Last reviewed · How we verify

NCT06313359

Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.

Recruiting now Last updated 3 September 2025
What this trial tests

trial in Peripheral Neuropathy Due to Chemotherapy in 40 participants. Currently enrolling.

Timeline
30 March 2024
Primary endpoint
30 December 2025
30 June 2026

Quick facts

Lead sponsorTexas Woman's University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment40
Start date30 March 2024
Primary completion30 December 2025
Estimated completion30 June 2026
Sites1 location across United States

Conditions studied

Sponsor

Texas Woman's University

Who can join

18 and older, any sex, with Peripheral Neuropathy Due to Chemotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to examine the impact of peripheral neuropathy on fall risk and quality of life in people who had cancer and neuropathy from cancer treatments. The investigators are interested to find out if the participant have any difficulty with thinking, feeling, balancing, or moving around that will contribute to risk for falls or quality of life. Investigators are also interested to see if the participants have any difficulty with doing two activities at the same time, such as walking and texting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Peripheral Neuropathy Due to Chemotherapy

Currently open trials in the same condition.

Other Texas Woman's University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06313359.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing